Related Experiment Videos
Platelet-melanoma cell interaction is mediated by the glycoprotein IIb-IIIa complex
H Boukerche1, O Berthier-Vergnes, E Tabone
1Faculté de Médicine Alexis Carrel, INSERM Unite 63, Lyon, France.
Abstract:
A human malignant melanoma cell line (M3Dau) was observed by electron microscopy to interact directly with human platelets and induced platelet aggregation. Fab fragments of a monoclonal antibody MoAb (LYP18), directed against the platelet glycoprotein (GP) IIb-IIIa complex, inhibited platelet-melanoma interactions and platelet-platelet aggregation. M3Dau melanoma cells bind LYP 18 and synthesize IIb-IIIa-like GPs. When the melanoma cells were preincubated with LYP 18, tumor-platelet interaction did not occur, suggesting that the interaction may be mediated by the IIb-IIIa-like GPs present on the melanoma cell surface. Glanzmann's thrombasthenic platelets, lacking GPIIb and IIIa, did not interact with melanoma cells, indicating that the platelet GPIIb-IIIa complex is also necessary for the platelet-melanoma cell interaction. This work demonstrates the importance of the IIb-IIIa-like GPs, present on M3Dau melanoma cells, in mediating tumor-platelet interactions.
Insights
Melanoma cells interact with platelets via a mechanism involving platelet glycoprotein (GP) IIb-IIIa. This interaction is crucial for tumor cell adhesion and can be blocked by antibodies targeting this GP complex.
Area of Science:
- Oncology
- Hematology
- Cell Biology
Background:
- Malignant melanoma cells can interact with human platelets.
- Platelet aggregation is a key process in hemostasis and thrombosis.
- The glycoprotein (GP) IIb-IIIa complex on platelets plays a critical role in platelet aggregation.
Purpose of the Study:
- To investigate the molecular mechanisms underlying the interaction between M3Dau melanoma cells and human platelets.
- To determine the role of platelet glycoprotein (GP) IIb-IIIa in melanoma cell-platelet interactions.
Main Methods:
- Electron microscopy to visualize cell interactions.
- Monoclonal antibody (LYP18) inhibition assays targeting the GP IIb-IIIa complex.
- Use of Glanzmann's thrombasthenic platelets (lacking GP IIb-IIIa) for interaction studies.
Main Results:
- M3Dau melanoma cells directly interact with and induce aggregation of human platelets.
- The monoclonal antibody LYP18, targeting GP IIb-IIIa, inhibited melanoma-platelet interactions and aggregation.
- M3Dau melanoma cells express IIb-IIIa-like glycoproteins that bind LYP18.
- Glanzmann's thrombasthenic platelets failed to interact with M3Dau melanoma cells.
Conclusions:
- The interaction between M3Dau melanoma cells and platelets is mediated by IIb-IIIa-like glycoproteins on the melanoma cell surface.
- The platelet GP IIb-IIIa complex is essential for this tumor-platelet interaction.
- Targeting the IIb-IIIa pathway may offer a strategy to inhibit melanoma cell adhesion to platelets.